# CheckMate 142

Source: https://onco.cc/trials/checkmate-142/  
OnCo record `checkmate-142` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

The trial that first showed checkpoint immunotherapy works in mismatch-repair deficient bowel cancer, and that adding a second antibody makes it work better.

## Summary

CheckMate 142 is the multi-cohort phase 2 that established immunotherapy in mismatch-repair deficient metastatic colorectal cancer. In the nivolumab-with-ipilimumab dMMR cohort of 119 patients, 76 percent of whom had received two or more previous systemic therapies, the investigator-assessed objective response rate was 55 percent (95% CI 45.2 to 63.8) and disease control for at least twelve weeks 80 percent; median duration of response was not reached and 94 percent of responses were continuing at data cutoff. Progression-free survival was 76 percent at nine months and 71 percent at twelve, and overall survival 87 and 85 percent. Grade 3 to 4 treatment-related events affected 32 percent. The microsatellite-stable cohorts were the mirror image: a later report of nivolumab, ipilimumab and cobimetinib in 30 patients with MSS or proficient mismatch repair disease found an objective response rate of 3 percent and median overall survival 8.2 months, and concluded that the regimen should not be pursued. CheckMate 142 led to the 2017 and 2018 accelerated approvals and set up KEYNOTE-177 and CheckMate 8HW.

## Fields

- Kind: Trial
- Status: positive
- Last checked: 2026-09-24
- Registry id: NCT02060188
- Phase: 2
- Setting: Recurrent or metastatic colorectal cancer, MSI-high and non-MSI-high cohorts: nivolumab alone or with ipilimumab, and later cohorts adding cobimetinib, daratumumab or relatlimab
- Sponsor: Bristol Myers Squibb
- Enrolled: 385
- Result: dMMR nivolumab plus ipilimumab cohort: objective response 55 percent, twelve-month overall survival 85 percent. MSS cohort with cobimetinib: objective response 3 percent.
- Outcomes: Objective response rate (dMMR, nivolumab plus ipilimumab): Nivolumab plus ipilimumab 55 percent; Objective response rate (MSS, nivolumab, ipilimumab and cobimetinib): Nivolumab, ipilimumab and cobimetinib 3 percent
- Replication: KEYNOTE-177 and CheckMate 8HW confirmed the dMMR effect in randomised phase 3 trials; the MSS cohorts agree with IMblaze370.

## Sources

- ClinicalTrials.gov NCT02060188: https://clinicaltrials.gov/study/NCT02060188
- CheckMate 142: durable clinical benefit with nivolumab plus ipilimumab in dMMR metastatic colorectal cancer (Journal of Clinical Oncology 2018): https://doi.org/10.1200/JCO.2017.76.9901
- CheckMate 142: nivolumab, ipilimumab and cobimetinib in MSS metastatic colorectal cancer (ESMO Gastrointestinal Oncology 2026): https://doi.org/10.1016/j.esmogo.2026.100334

## Connected records

- cancers: [Colorectal cancer](https://onco.cc/cancers/colorectal/), [Mismatch-repair deficient (MSI-high) colorectal cancer](https://onco.cc/cancers/msi-high-colorectal/)
- technologies: [Immune checkpoint inhibitors](https://onco.cc/technologies/checkpoint-inhibitor/)
- targets: [CTLA-4](https://onco.cc/targets/ctla4/), [MEK1/2](https://onco.cc/targets/mek/), [PD-1](https://onco.cc/targets/pd1/)
- drugs: [Cobimetinib](https://onco.cc/drugs/cobimetinib/), [Ipilimumab](https://onco.cc/drugs/ipilimumab/), [Nivolumab](https://onco.cc/drugs/nivolumab/)
- companies: [Bristol Myers Squibb](https://onco.cc/companies/bms/)
- terms: [Hot vs cold tumours](https://onco.cc/terms/cold-vs-hot/), [Microsatellite instability (MSI-H) / mismatch repair deficiency (dMMR)](https://onco.cc/terms/msi/)
- trials: [CheckMate 8HW](https://onco.cc/trials/checkmate-8hw/), [IMblaze370](https://onco.cc/trials/imblaze370/), [KEYNOTE-177](https://onco.cc/trials/keynote-177/)

---
JSON: https://onco.cc/api/v1/entities/checkmate-142.json